Axsome Therapeutics (AXSM) EBT Margin: 2022-2025
Historic EBT Margin for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to -27.62%.
- Axsome Therapeutics' EBT Margin rose 3404.00% to -27.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -41.05%, marking a year-over-year increase of 5092.00%. This contributed to the annual value of -74.45% for FY2024, which is 1361.00% up from last year.
- Per Axsome Therapeutics' latest filing, its EBT Margin stood at -27.62% for Q3 2025, which was up 15.31% from -32.61% recorded in Q2 2025.
- In the past 5 years, Axsome Therapeutics' EBT Margin ranged from a high of -9.13% in Q1 2023 and a low of -266.08% during Q3 2022.
- For the 3-year period, Axsome Therapeutics' EBT Margin averaged around -74.31%, with its median value being -63.00% (2024).
- As far as peak fluctuations go, Axsome Therapeutics' EBT Margin surged by 15,728bps in 2023, and later crashed by 8,201bps in 2024.
- Axsome Therapeutics' EBT Margin (Quarterly) stood at -251.29% in 2022, then surged by 11,292bps to -138.37% in 2023, then skyrocketed by 7,537bps to -63.00% in 2024, then soared by 3,404bps to -27.62% in 2025.
- Its last three reported values are -27.62% in Q3 2025, -32.61% for Q2 2025, and -48.91% during Q1 2025.